Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Genzyme Wins AnorMED As Millennium Backs Out Of Bidding War

This article was originally published in The Pink Sheet Daily

Executive Summary

Genzyme gains late-stage product candidate Mozobil for approximately $580 mil.

You may also be interested in...



Genzyme Reports Positive Phase III Results For Mozobil In Stem Cell Transplant

NDA filing for patients undergoing hematopoietic stem cell transplant for NHL is anticipated in first half of 2008.

Genzyme Reports Positive Phase III Results For Mozobil In Stem Cell Transplant

NDA filing for patients undergoing hematopoietic stem cell transplant for NHL is anticipated in first half of 2008.

Genzyme Executive VP-Legal And Corporate Development Peter Wirth: An Interview With “The Pink Sheet” DAILY (Part 3 of 3)

Wirth discusses personalized medicine and Genzyme’s development pipeline, including further plans for Mozobil.

Related Content

Topics

UsernamePublicRestriction

Register

ID1132090

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel